Company Analysis
Sign in

Cardiff Oncology, Inc. (CRDF)

Nasdaq: CRDF · Biological Products, (No Diagnostic Substances) · San Diego, CA · filing with the SEC since 2003
Full chart Alerts Compare
Grade4.4
◀ Past 4.9● Present 3.7▶ Future 4.8
1 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Income statement, as filed

In US dollars (USD), as filed; per-share figures in US dollars; share counts. The fiscal year ends in December.
Income statement, by fiscal year, newest first
Fiscal yearFY 2025FY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018FY 2017FY 2016
Period endingDec 31, 2025Dec 31, 2024Dec 31, 2023Dec 31, 2022Dec 31, 2021Dec 31, 2020Dec 31, 2019Dec 31, 2018Dec 31, 2017Dec 31, 2016
Report filedFeb 24, 2026Feb 27, 2025Feb 29, 2024Mar 2, 2023Feb 24, 2022Feb 25, 2021Feb 27, 2020Mar 6, 2019Feb 26, 2018Mar 15, 2017
Revenue593,000683,000488,000386,000359,000366,000244,632378,325505,404381,072
For lenders
Net interest income·········-1,375,512
Cost of revenue······0597,4571,811,4241,730,512
Research and development35,329,00036,852,00032,857,00027,107,00017,376,00011,235,000r11,162,2368,164,0117,882,65015,006,642
Selling, general and administrative14,224,00012,482,00013,043,00013,181,00011,838,0008,217,000r5,760,8908,005,58314,232,876·
Sales and marketing········2,735,41011,523,144
General and administrative········11,497,46611,475,947
Total operating expenses49,553,00049,334,00045,900,00040,288,00029,214,00019,452,000r16,923,12617,431,73726,101,20140,526,683
Operating income-48,960,000-48,651,000-45,412,000-39,902,000-28,855,000-19,086,000r-16,678,494-17,053,412-25,595,797-40,145,611
Interest expense····02,000r025,4091,033,9391,674,341
Interest and investment income3,104,0003,259,0004,069,0001,581,000264,00090,000r234,169219,430147,883298,829
Other income (expense), net5,000-39,000-98,000·······
Total non-operating income (expense)3,109,0003,220,0003,971,0001,198,000564,000-221,000····
Income before income taxes-45,851,000-45,431,000········
Income tax expense0000000000
Net income-45,851,000-45,431,000-41,441,000-38,704,000-28,291,000-19,307,000r-16,414,159-16,461,178-24,906,744-39,203,719
Preferred dividends25,00024,00024,00024,00024,00024,000r24,24024,24024,24024,240
Net income to common shareholders-45,876,000-45,455,000-41,465,000-38,728,000-28,315,000-22,598,000r-16,706,668-19,254,951-24,930,984-39,227,959
Earnings per share, basic-0.69-0.95-0.93-0.89-0.73-1.08·-8.26-51.76r-93.60b
Earnings per share, diluted-0.69-0.95-0.93-0.89-0.73-1.08·-8.26-51.76r-98.64b
Earnings per share, basic and diluted·····-1.08-2.80-8.26··
Weighted average shares, basic66,841,00047,650,00044,677,00043,600,00039,030,00020,875,0005,973,9062,330,180481,672r419,095b
Weighted average shares, diluted66,841,00047,650,00044,677,00043,600,00039,030,00020,875,000·2,330,180481,672r420,573b
Weighted average shares, basic and diluted·····20,874,6655,973,9062,330,180··
As filed with the SEC, each figure from the newest report that carries it, and linked to it. Nothing here is computed.Share counts and per-share figures are on the newest report's basis, after the 1-for-72 reverse split.A dot is a line not tagged for that period. r restated by the company in a later report; b a share figure put on the newest basis or filed in the wrong unit. Hover a figure for its filing and note.
What each line is, and the XBRL concept behind it
Revenue what customers paid for what it soldus-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
us-gaap:Revenues
us-gaap:SalesRevenueNet
Net interest income interest earned less interest paidus-gaap:InterestIncomeExpenseNet
Cost of revenue what it cost to make or buy what it soldus-gaap:CostOfRevenue
Research and development spent on inventing what it sells nextus-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
Selling, general and administrative the cost of selling and of running the companyus-gaap:SellingGeneralAndAdministrativeExpense
Sales and marketing the cost of finding and serving customersus-gaap:SellingAndMarketingExpense
General and administrative the cost of running the company itselfus-gaap:GeneralAndAdministrativeExpense
Total operating expenses the running costs togetherus-gaap:OperatingExpenses
Operating income profit from running the business, before interest and taxus-gaap:OperatingIncomeLoss
Interest expense what its borrowing costus-gaap:InterestExpense
Interest and investment income what its cash and investments earnedus-gaap:InvestmentIncomeInterest
Other income (expense), net gains and costs outside the businessus-gaap:OtherNonoperatingIncomeExpense
Total non-operating income (expense) everything outside the business, togetherus-gaap:NonoperatingIncomeExpense
Income before income taxes profit before taxus-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
Income tax expense tax charged on the period's profitus-gaap:IncomeTaxExpenseBenefit
Net income the profit or loss that belongs to the company's shareholdersus-gaap:NetIncomeLoss
Preferred dividends paid to preferred holders before common shareholdersus-gaap:PreferredStockDividendsIncomeStatementImpact
Net income to common shareholders what is left for common shareholdersus-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
Earnings per share, basic net income per share outstandingus-gaap:EarningsPerShareBasic
Earnings per share, diluted net income per share, counting every share that could be issuedus-gaap:EarningsPerShareDiluted
Earnings per share, basic and diluted net income per share, where both counts are the sameus-gaap:EarningsPerShareBasicAndDiluted
Weighted average shares, basic the average count of shares outstandingus-gaap:WeightedAverageNumberOfSharesOutstandingBasic
Weighted average shares, diluted the average count with every share that could be issuedus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Weighted average shares, basic and diluted the average count, where both counts are the sameus-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted
SI Assistanton CRDF · research, not advice